Drug intelligence / Profile preview

ethyl pyruvate

Development stage
Phase 4
Modality
Small Molecules
Administration
Oral, Topical, Intravenous, Intraperitoneal
01

Overview

Ethyl pyruvate is a small molecule derivative of the endogenous metabolite pyruvic acid. It has been investigated primarily as an anti-inflammatory and tissue-protective agent in various preclinical models of critical illnesses, including sepsis, acute pancreatitis, ischemia-reperfusion injury, renal injury, endotoxemia, and stroke. Ethyl pyruvate acts by inhibiting the systemic release of pro-inflammatory cytokines such as Tumor necrosis factor alpha and High mobility group box 1 protein, which are implicated in severe organ damage during critical care conditions. Its mechanism also involves modulation of redox processes and cellular metabolism; it may provide exogenous pyruvate to fuel cell metabolism and influence energy production through activation of Nuclear factor erythroid 2-related factor 2 signaling pathways. Ethyl pyruvate has demonstrated safety in human volunteers at clinically relevant doses but remains investigational for therapeutic use[1][2][3][4][5][6].

Other names
pyruvic acid ethyl ester2-oxo-propionate ethyl esterEP
02

Targets

HMGB1 (High mobility group protein B1)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on ethyl pyruvate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ethyl pyruvate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call